Figure 6
![CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/128/4/10.1182_blood-2015-11-683847/4/519f6.jpeg?Expires=1721636318&Signature=ZdO4gVbfAumOCduBPsAL9qr2N~MdeC2DnHqNTZYDziPRyHlHF9fckPbP6xfRwk65nvVbY7GiJkvpYamx483ouGL12k-gNB~ENSCedHAvFbiVRDKkAWAyEUEifq34g2FC-gx4dreOFQD-RTC97Vj67AOQKHhrHVq4wGL1XVJaz5AenvlfYv6xd3cj7blQZ1lm2CLpmvDnQgru5ro5TQmQFsgXR-~pgXInkcXDobxsZHqlZftNIUyg7ju4WWMG1eo5xczgEgRvXvmPGvqe7ju~lXIF~YL7D2IkCt8HY2-Ljyz1eUAjW6Uwvj3lET8Qu-064eYG1Z-FXUwWO2MzFI~iQg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CD19-CAR–modified TSCM mediate long-lasting antitumor responses. (A) In vivo bioluminescent imaging, (B) radiance, and (C) survival of NSG mice bearing systemic NALM6-GL leukemia xenografts after adoptive transfer of CD19-CAR–modified standard or TSCM-enriched CD8+ T cells (2.5 × 105) in conjunction with intraperitoneal injections of recombinant human IL-15 every other day (****P < .0001; log-rank [Mantel-Cox]; n = 5). Data shown are representative of 2 independent experiments. d, day.
